A new furanoditerpene from Saururus chinensis aerial parts

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-11-20 DOI:10.1016/j.phytol.2024.11.009

Thi Tu Oanh Nguyen , Thi Minh Hang Nguyen , Mai Thao Vu , Yohan Seo , SeonJu Park , Van Cuong Pham , Van Hung Nguyen , Xuan Nhiem Nguyen

引用次数: 0

Abstract

A new furanoditerpene, saurufuranol (1) along with a flavonoid, 3,5,7,3′,4′-pentamethoxyflavone (2), and eight lignans including macelignan (3), 5-((2R,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl)benzo[d][1,3]dioxole (4), dihydroguaiaretic acid (5), (+)-zuonin A (6), sauchinone (7), saucerneol A (8), manassantin A (9) and saucerneol C (10). Their structures were determined by extensive spectroscopic studies using NMR spectroscopy and mass spectrometry in combination with literature. These compounds were evaluated cytotoxicity on PC-9 and HT-29 cancer cell line. Compound 8 showed significant activity on both of cancer cell lines with IC₅₀ values of 1.33±0.23 and 1.18±0.27 µM, respectively.

查看原文本刊更多论文

从金鸡纳树气生部分提取的一种新的呋喃二萜

一种新的呋喃二萜，saurufuranol (1)和一种类黄酮，3,5,7,3′,4′-五甲氧基黄酮(2)，以及八种木脂素，包括macelignan (3)，5-((2R,3R)-4-(3、(2R,3R)-4-(3,3-二甲氧基苯基)-2,3-二甲基丁基)苯并[d][1,3]二恶茂(4)、二氢愈创木脂酸(5)、(+)-zuonin A (6)、苏木酮(7)、苏木醇 A (8)、马纳桑汀 A (9) 和苏木醇 C (10)。通过使用核磁共振光谱和质谱进行广泛的光谱研究，并结合文献资料，确定了这些化合物的结构。评估了这些化合物对 PC-9 和 HT-29 癌细胞系的细胞毒性。化合物 8 对这两种癌细胞株都有明显的活性，其 IC50 值分别为 1.33±0.23 和 1.18±0.27 µM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.